Cited by 286Cardiovascular Function and Risk FactorsHeart Failure Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction

Open access
Dries, Daniel L, Sweitzer, Nancy K, Drazner, Mark H, Stevenson, Lynne W, Gersh, Bernard J·2001·Journal of the American College of Cardiology

Abstract

Objectives We sought to determine the relative impact of diabetes mellitus on prognosis in ischemic compared with nonischemic cardiomyopathy.Background Ischemic myocardium is characterized by increased reliance on aerobic and anaerobic glycolysis. Because glucose utilization by cardiomyocytes is an insulin-mediated process, we hypothesized that diabetes would have a more adverse impact on mortality and progression of heart failure in ischemic compared with nonischemic cardiomyopathy.Methods We performed a retrospective analysis of the Studies Of Left Ventricular Dysfunction (SOLVD) Prevention and Treatment trials.Results In adjusted analyses, diabetes mellitus was strongly associated with an increased risk for all-cause mortality in patients with ischemic cardiomyopathy, (relative risk [RR] 1.37, 95% confidence interval [CI] 1.21 to 1.55; p < 0.0001), but not in those with nonischemic cardiomyopathy (RR 0.98, 95% CI 0.76 to 1.32; p = 0.98). The increased mortality in patients with ischemic cardiomyopathy compared with nonischemic cardiomyopathy was limited to those with ischemic cardiomyopathy and diabetes mellitus (RR 1.37, 95% CI 1.21 to 1.56; p < 0.0001). When patients with ischemic cardiomyopathy and diabetes mellitus were excluded, there was no significant difference in mortality risk between the ischemic and nonischemic cardiomyopathy groups after adjusted analysis (RR 0.99, 95% CI 0.86 to 1.15; p = 0.99). Previous surgical revascularization identified patients within the cohort with ischemic cardiomyopathy and diabetes mellitus, with improved prognosis.Conclusions The differential impact of diabetes on mortality and heart failure progression according to the etiology of heart failure suggests that diabetes and ischemic heart disease interact to accelerate the progression of myocardial dysfunction. Evaluation of the potential for revascularization may be particularly important in patients with ischemic cardiomyopathy and diabetes mellitus.

Integrity signals

Registry

Crossref · 10.1016/s0735-1097(01)01408-5

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Dries, D. L., Sweitzer, N. K., Drazner, M. H., Stevenson, L. W., & Gersh, B. J.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Brigham and Women's Hospital (US)
  • Mayo Clinic (US)
Corresponding author
Dries, Daniel L
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2001-08
Volume
38
Issue
2
Pages
421-428
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2110103927
Cited by
286
References
19
Citations by year
2026: 1 · 2025: 1 · 2024: 5 · 2023: 1 · 2022: 9 · 2021: 3 · 2020: 17 · 2019: 9 · 2018: 17 · 2017: 9 · 2016: 12 · 2015: 9 · 2014: 11 · 2013: 9 · 2012: 12
FWCI
10.96
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
diabetes mellitus, heart failure, left ventricular systolic dysfunction, ischemic cardiomyopathy, non-ischemic cardiomyopathy, all-cause mortality, heart failure progression, revascularization, myocardial glucose utilization, insulin, SOLVD trial
MeSH terms
Coronary Artery Bypass, Female, Heart Failure, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Systole, Cohort Studies, Survival Rate, Myocardial Ischemia, Ventricular Dysfunction, Left, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review